Adjuvant effect of hydrochlorothiazide on radioiodine treatment in low-iodine uptake Graves’ disease patients

Authors

  • Maythinee Chantadisai Faculty of Medicine, Chulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
  • Supatporn Tepmongkol Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Keywords:

Hyperthyroidism, diuretics, radioiodine treatment, remission, Iodine radioisotopes

Abstract

Background: The outcome of radioiodine (RAI) treatment in Graves’ disease patients depends mostly on the percentage of RAI uptake in the thyroid gland. Most Graves’ disease patients have a high percentage of RAI uptake while some have low uptake even after continuation of a low-iodine diet before RAI treatment. Hydrochlorothiazide has been proven to increase the percentage of uptake in low-iodine diet low-uptake Graves’ disease patients. However, the effect on the patient’s outcome has never been demonstrated.

Objective: The aim of this study was to investigate the outcome of RAI treatment in low-iodine uptake Graves’ disease patients who were pre-treated with hydrochlorothiazide (HCTZ). The results were then compared with those who continued the low-iodine diet alone.

Methods: All patients had Graves’ disease and had low iodine uptake at baseline (1st RAI uptake). This retrospective study aimed to compare the treatment outcomes between two groups. The control group consisted of patients who discontinued an iodine-containing diet for 2 weeks before the 2nd RAI uptake. The HCTZ group consisted of patients who discontinued an iodine-containing diet for 2 weeks together with 50 mg of HCTZ in two divided doses for 5 days before the 2nd RAI uptake. 131 I treatment doses were calculated based on the size of the thyroid gland, and the second 24-hr RAI uptake. The outcomes of treatment were then compared between the two groups at 3, 6, 9 and 12 months after treatment.

Results: There were 13 subjects in each group. At baseline, there was significantly higher 24-hr RAI uptake in the control group than the HCTZ group. However, in the second RAI uptake, the HCTZ group had significantly higher 3-hr and 24-hr uptake than the control group. Regarding the thyroid size, the HCTZ group had a larger mean of thyroid size than the control group. There was no significant difference in the percentage of remission at each time point between the two groups. However, after adjustment of the thyroid size and baseline 24-hr uptake, patients in the HCTZ group were 3.06 (adjusted OR = 3.06, 95%CI: 0.45, 20.68) times more likely to have disease remission than those in the control group, but this was not statistically significant.

Conclusions: Pre-treatment with HCTZ together with a low-iodine diet in low-uptake Graves’ disease patients are more likely to have a higher remission rate than using a low-iodine diet alone.

Downloads

Download data is not yet available.

References

Harsoulis F. Hyperthyroidism and nuclear medicine. Hell J Nucl Med 2000;3:6-10.

Sekulić V, Rajić MP, Vlajković MŽ, Ilić SS, Stević MLj, Kojić MM. Short term treatment with lithium carbonate as adjunct to radioiodine treatment for long-lasting Graves' hyperthyroidism. Hell J Nucl Med 2015;18:186-8.

Barakat RM, Ingbar SH. The effect of acute iodide depletion on thyroid function in man. J Clin Invest 1965;44:1117-24. https://doi.org/10.1172/JCI105218

Tepmongkol S. Enhancement of radioiodine uptake in hyperthyroidism with hydrochlorothiazide: a prospective randomised control study. Eur J Nucl Med Mol Imaging 2002;29:1307-10.

https://doi.org/10.1007/s00259-002-0893-3

Walter MA, Nitzsche EU, Müller-Brand J. Enhancement of radioiodine uptake in hyperthyroidism by administration of hydrochlorothiazide. Eur J Nucl Med Mol Imaging 2003;30:474.

https://doi.org/10.1007/s00259-002-1085-x

Poshyachinda M. Diagnosis and treatment of thyroid gland with radioactive 1 st. Bangkok: Charansanitwong Printing, 2008:1-376.

Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract 2011;17:456-520.

https://doi.org/10.4158/EP.17.3.456

Fregly MJ, McCarthy JS. Effect of diuretics on renal iodide excretion by humans. Toxicol Appl Pharmacol 1973;25:289-98. https://doi.org/10.1016/S0041-008X(73)80015-8

Beyer KH, Jr., Fehr DM, Gelarden RT, White WJ, Lang CM, Vesell ES. Hydrochlorothiazide-induced 131I excretion facilitated by salt and water. J Clin Pharmacol 1981;21:201-12.

https://doi.org/10.1002/j.1552-4604.1981.tb02549.x

Matovic MD, Jankovic SM, Jeremic M, Novakovic M, Milosev M, Vlajkovic M. Effect of furosemide on radioiodine-131 retention in mice thyroid gland. Hell J Nucl Med 2009;12:129-31.

Seabold JE, Ben Haim S, Pettit WA, Gurli NJ, Rojeski MT, Flanigan MJ, et al. Diuretic-enhanced I-131 clearance after ablation therapy for differentiated thyroid cancer. Radiology 1993;187: 839-42.

https://doi.org/10.1148/radiology.187.3.8497641

Matovic MD, Jankovic SM, Jeremic M, Tasic Z, Vlajkovic M. Unexpected effect of furosemide on radioiodine urinary excretion in patients with differentiated thyroid carcinomas treated with iodine 131. Thyroid 2009;19:843-8. https://doi.org/10.1089/thy.2008.0400

Ignjatovic VD, Vukomanovic V, Jeremic M, Ignjatovic VS, Matovic M. Influence of hydrochlorothiazide on urinary excretion of radioiodine in patients with differentiated thyroid cancer. Acta Endo (Buc) 2015;11:396-400. https://doi.org/10.4183/aeb.2015.396

Barbaro D, Grosso M, Boni G, Lapi P, Pasquini C, Orsini P, et al. Recombinant human TSH and ablation of post-surgical thyroid remnants in differentiated thyroid cancer: the effect of pre-treatment with furosemide and furosemide plus lithium. Eur J Nucl Med Mol Imaging 2010;37:242-9.

https://doi.org/10.1007/s00259-009-1254-2

Kapucu LO, Azizoglu F, Ayvaz G, Karakoc A. Effects of diuretics on iodine uptake in non-toxic goitre: comparison with low-iodine diet. Eur J Nucl Med Mol Imaging 2003;30:1270-2.

https://doi.org/10.1007/s00259-003-1251-9

Downloads

Published

2023-08-04

How to Cite

1.
Chantadisai M, Tepmongkol S. Adjuvant effect of hydrochlorothiazide on radioiodine treatment in low-iodine uptake Graves’ disease patients. Chula Med J [Internet]. 2023 Aug. 4 [cited 2024 Oct. 12];63(1). Available from: https://he05.tci-thaijo.org/index.php/CMJ/article/view/268